MedWatch

Doctors represent hurdle for Lundbeck once again

Lundbeck’s research & development boss, Anders Gersel Pedersen, is pleased with the label given by the FDA to the company’s new potential blockbuster, antidepressant Brintellix. But the success of the product depends on the efficiency of commercial partner Takeda’s marketing machinery.

Foto: PR

Antidepressant Brintellix has been approved for the US market, and it should merely be a matter of time before billions starting rolling into the accounts of Lundbeck and Japanese partner Takeda. The biggest hurdle for the product is to convince doctors that the drug is as good as the two companies believe it to be, a notion that is backed by a number of clinical trials.

Anders Gersel Pedersen, VP in charge of Research & Development in Lundbeck, is highly pleased with the approval, and he notes that FDA has given the companies what they wanted in the form of a great label and recognition of the many beneficial aspects of the drug, as the VP puts it.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Lundbeck sætter ekstra skub i arbejdet med potentiel vækstmotor

Lundbeck skruer forud for en amerikansk ansøgning senere på året nu op for forberedelserne med brexpiprazol som behandling af vredesudbrud hos Alzheimers-patienter. Det sker, efter at midlet tidligere på sommeren har vist positive resultater i et fase 3-studie.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier